Cysbio

Cysbio is a Danish biotechnology company founded in 2019 that specializes in advanced metabolic engineering and synthetic biology. The company constructs proprietary bacterial cell factories designed to transform the production of biochemicals using renewable feedstocks. Its core technology platform focuses on producing selected amino acids through fermentation processes that achieve high yields and titers. Additionally, Cysbio has developed a patented sulfation technology that enables the enzymatic production of various sulfated phenolic compounds. This technology allows for the creation of novel molecules, the cost-effective production of existing chemicals, and the detoxification of otherwise toxic compounds, which can improve the solubility and bioavailability of various drugs.

The company's innovations address significant manufacturing challenges in the pharmaceutical, food, animal feed, and polymer industries. By utilizing fermentation as a sustainable, cost-effective alternative to traditional production methods, Cysbio provides industrial partners with solutions for scaling up the manufacture of essential biochemicals. Their work has been supported by various research grants, including participation in EU-funded programs such as Horizon 2020. Based in Hørsholm, Denmark, Cysbio operates as a manufacturer and innovator, maintaining a strong focus on strategic industrial partnerships to further develop and commercialize their bio-based product portfolio.